Discover why Zacks SCR has lifted its price target on BSEM shares again. ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Huge Alerts.
2024 has been a record year with both Q1 and Q2 results for BSEM and now Q3 results are in… The quarter is now another epic testament to the company’s growth! The biotech space staged a comeback in late 2023 and early 2024 as Big Pharma tapped into takeovers again. In mid-July biotech tech stocks even hit a two-year high. One biotech company with exciting developments that looks to be going underfollowed is BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care. The company is addressing two multi-billion dollar markets and has seen record breaking quarterly results all year.
BSEM recently reported that for the third quarter the company achieved another major milestone with its third consecutive quarter of record growth. In Q3 2024, the company posted revenue of $82.6 million for the quarter, totaling $199 million for the first nine-months of 2024. This strong financial performance is a direct result of the continued success of our AmnioWrap2® allografts using the company’s patented BioREtain® technology, which is driving increased commercial acceptance across a wide range of non-acute sites of service. Following these results, Zacks SCR updated its price target from $24.25 to $32.50!! AND ON ANOTHER EXCITING FRONT THAT COULD SERVE AS A CATALYST FOR GROWTH IS THAT A NASDAQ LISTING COULD BE AROUND THE CORNER FOR THE COMPANY! BSEM recently announced that it has filed with the SEC to register its shares pursuant to the Securities Exchange Act of 1934, which is an important step in its plan to uplist to the Nasdaq stock exchange. Discover how BSEM on the NASDAQ would open up the stock to new investors, especially on the institutional front and lead to shareholder growth Huge Alerts |
Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431 We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of BioStem Technologies Inc. (OTC: BSEM). The compensation consists of up to $2,500 and was received/will be received from Sideways Frequency. This compensation should not be considered as an endorsement of the securities of adviser BioStem Technologies Inc. (OTC: BSEM) and we are not responsible for any errors or omissions in any information provided about the securities of BioStem Technologies Inc. (OTC: BSEM) by Huge Alerts. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 11/18/24. Behind the Markets
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. Today's Bonus Content: My 402 Dividend Achievers of 2025 (By clicking this link you agree to receive emails from Trading Tips and our affiliates. You can opt out at any time) |
|
No comments:
Post a Comment